KPC Pharmaceuticals, Inc. (600422): Under severe external conditions, lower before 2024, higher after.

The company announced the 2024 performance preliminary report, with revenue, net profit attributable to shareholders, and profit excluding non-recurring items achieving 8.4, 0.65, and 0.44 billion yuan respectively, a year-on-year increase of 9%, 46%, and 30%. After restating adjustments (considering the consolidation of Shenghuo), it shows a year-on-year growth of 0.

HTSCFeb 12 11:48

Announcement of KPC on the 2024 Annual Results Report

SZSIFeb 11 00:00 · Announcements

CHINARES PHARMA (03320.HK) subsidiary KPC Pharmaceuticals, Inc. earned 0.648 billion RMB last year, which represents a growth of 19.9%.

CHINARES PHARMA (03320.HK) announced the preliminary performance of its subsidiary KPC Pharmaceuticals, Inc. for the 2024 fiscal year, with total operating revenue of 8.401 billion RMB (the same below), a slight decrease of 0.3% compared to the previous year (after retrospection adjustment). The net profit attributable to Shareholders is 0.648 billion yuan, an increase of 19.9%, with earnings per share of 86 cents.

AASTOCKSFeb 10 23:34

KPC Pharmaceuticals Records 46% Higher Net Attributable Profit in 2024

MT NewswiresFeb 10 20:13

KPC Pharmaceuticals, Inc. (600422.SH) reported a net income of 0.648 billion yuan for the 2024 fiscal year, an increase of 19.86% year-on-year.

KPC Pharmaceuticals, Inc. (600422.SH) disclosed the annual performance report for 2024, in which the company is fully promoting...

Zhitong FinanceFeb 10 17:42

Express News | KPC Pharmaceuticals, Inc.: The net income for 2024 is 0.648 billion yuan, an increase of 19.86% year-on-year.

BreakingsFeb 10 17:32